Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 9/20 | 0.59 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.59 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.59 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.59 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.59 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.59 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | MLNR | O43193 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL3280551 | 1.00 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL3137768 | 1.00 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Cadaverine Tartrate SCHEMBL2450635 | 1.00 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL1535363 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL3312526 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL2740 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Succinic Acid SCHEMBL5530810 | 0.91 | CACNA2D1 (0.65) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Succinic Acid SCHEMBL5512390 | 0.91 | CACNA2D1 (0.65) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3592 | 0.90 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL521869 | 0.90 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132192-B1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LTD (IN) | 2013-04-24 | — | — | EP | disclosed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| EP-1857451-B1 | A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine | FIDIA FARMACEUTICI (IT) | 2010-07-21 | — | — | EP | disclosed |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2010-04-29 | — | — | US | disclosed |
| EP-2132192-A2 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | Lupin Limited (IN) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107911-A2 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2008-09-12 | — | — | WO | disclosed |
| EP-1857451-A1 | A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine | SOLMAG S.p.A. (IT) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | MAOA, SLC6A3, PNMT | SLC6A2 19/4885SLC6A3 2/4885ADRB1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.